WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018016657) ETHYL 6-[(2-CHLORO-4-FLUOROPHENYL)METHANESULFONYL]-3-METHYLCYCLOHEX-1-ENE-1-CARBOXYLATE AS TLR4 ANTAGONIST
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/016657 International Application No.: PCT/JP2017/027137
Publication Date: 25.01.2018 International Filing Date: 20.07.2017
IPC:
A61K 31/235 (2006.01) ,C07C 317/44 (2006.01) ,A61P 25/08 (2006.01) ,A61P 25/18 (2006.01) ,A61P 25/28 (2006.01)
Applicants: TAKEDA PHARMACEUTICAL COMPANY LIMITED[JP/JP]; 1-1, Doshomachi 4-chome, Chuo-ku, Osaka-shi, Osaka 5410045, JP
Inventors: KOBAYASHI, Toshitake; JP
SAITOH, Morihisa; JP
WADA, Yasufumi; JP
NEGORO, Nobuyuki; JP
Agent: TAKASHIMA, Hajime; Meiji Yasuda Seimei Osaka Midosuji Bldg. 1-1, Fushimimachi 4-chome Chuo-ku, Osaka-shi Osaka 5410044, JP
Priority Data:
1612652.621.07.2016GB
Title (EN) ETHYL 6-[(2-CHLORO-4-FLUOROPHENYL)METHANESULFONYL]-3-METHYLCYCLOHEX-1-ENE-1-CARBOXYLATE AS TLR4 ANTAGONIST
(FR) ÉTHYL 6- [(2-CHLORO-4-FLUOROPHÉNYL) MÉTHANESULFONYL]-3-MÉTHYLCYCLOHEX-1-ÈNE-1-CARBOXYLATE EN TANT QU'ANTAGONISTE DE TLR4.
Abstract:
(EN) The invention provides a compound of ethyl 6- [ (2-chloro- 4-fluorophenyl)methanesulfonyl] -3-methylcyclohex-1-ene-1- carboxylate. The compound possesses an advantageous combination of TLR4 antagonist properties and brain permeability, and therefore, the compound would be expected to be useful in the treatment of central nervous system diseases mediated at least in part by TLR4.
(FR) L'invention porte sur un composé de 6-[(2-chloro-4-fluorophényl) méthanesulfonyl]-3-méthylcyclohex-1-ène-1-carboxylate d'éthyle. Le composé est un antagonistes du TLR4 qui passe la barrière hématoencéphalique. Par conséquent, on s'attend à ce que le composé puisse être utilisé dans le traitement de maladies du système nerveux central provoquées par le TLR4.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)